Business Wire

Ericsson Joins Avanci Video as a Licensor

8.4.2025 11:00:00 CEST | Business Wire | Press Release

Share

Avanci Video, the simple and efficient licensing solution for internet streaming services, today welcomed Ericsson as a new licensor. Built from its ongoing investments in multimedia technologies, Ericsson owns a substantial portfolio of essential patents for video technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250408314721/en/

Avanci Video is the one-stop patent licensing solution for internet streaming services. (Graphic: Avanci)

Avanci Video offers the option of a single, comprehensive license for internet streaming providers, covering the latest video technologies—AV1, H.265 (HEVC), H.266 (VVC), MPEG-DASH, and VP9. Spanning the relevant patent portfolios of 32 (and growing) licensors for multiple technology standards in one agreement, Avanci Video simplifies the licensing process, making it more efficient and predictable for streaming companies.

Christina Petersson, Chief Intellectual Property Officer at Ericsson, stated: "In today's rapidly evolving video streaming market, there is a strong demand for simplified and efficient patent licensing solutions. By joining Avanci Video, we aim to support the industry's need for a comprehensive approach to licensing essential video technologies. We believe Avanci Video is well-positioned to facilitate the use of cutting-edge technology, enabling streaming providers to access the latest advancements in video technologies efficiently."

Kasim Alfalahi, CEO of Avanci, added: "We are delighted to welcome Ericsson to Avanci Video. As a long-standing leader in multimedia innovation, Ericsson increases the value of the Avanci Video license offering, bringing us closer to providing the one-stop solution that we know the market wants to help accelerate adoption of new video technologies."

The value of one-stop licensing solutions is underscored by the rapid growth of the video streaming market, with billions of over-the-top (OTT) video users worldwide. This significant user base highlights the importance of streamlined licensing solutions to support continuing growth in the industry.

About Avanci Video

Internet video streaming is central to how we connect, communicate, and consume content. As demand grows for higher-quality, energy-efficient streaming, the technologies behind it—like AV1, H.265 (HEVC), H.266 (VVC), VP9, and MPEG-DASH—continue to evolve rapidly. These advances improve compression, reduce environmental impact, and enable seamless viewer experiences. Avanci Video offers a one-stop licensing solution for these essential technologies. By bringing together patents from a growing number of licensors into a single license, Avanci Video removes complexity and uncertainty from the patent licensing process—making it simpler, faster, and more predictable for streaming companies around the world. For more information, visit www.avanci.com/video.

About Avanci

Avanci believes that sharing patented technology can be simpler. A global independent intermediary not owned or controlled by licensors or licensees, Avanci works at the intersection of different industries. Our one-stop solutions are designed to bring efficiency, convenience, and predictability to the licensing process. Since 2016, Avanci has been driving innovation forward by making connections through our licensing platforms.
www.avanci.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250408314721/en/

Contacts

Media contact:
Mark Durrant
Vice President, Marketing & Communications
media@avanci.com
+1 (469) 480-2558 / +44 7875 276867

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye